tumor tissue CGP test
A proven portfolio of RUO and IVD kits powered by robust proprietary bioinformatics
Our automated bioinformatics delivers >99% sensitivity and specificity1 with a seamless sample-to-answer workflow and optimized user experience.
We continuously optimize our portfolio of precision oncology solutions while also adding new clinically-relevant biomarkers and insights as they emerge. Our proprietary platform is well validated and can consistently identify hard-to-detect biomarkers, like MSI and TMB, with a high degree of accuracy.
Our distributed model facilitates in-house precision oncology to bring it closer to patients and empower labs with full control over data and specimens. We’ve honed our end-to-end workflow, from library preparation through result, to make local CGP testing simpler than ever.
Innovating throughout the NGS workflow
From extracted DNA to automatically generated reports, PGDx has developed methods to optimize protocols and results. That helps make best-in-class CGP analysis accessible for any lab.